Koers Tiziana Life Sciences PLC London S.E.
Aandelen
GB00B28XMY25
Biotechnologie & Medisch Onderzoek
slotkoers
Andere beurzen
|
||
- GBX | - |
Omzet 2022 | - | Omzet 2023 | - | Marktkapitalisatie | 56,17 mln. 51,7 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | -15 mln. -13,81 mln. | Nettowinst (verlies) 2023 | -17 mln. -15,65 mln. | EV/omzet 2022 | - |
Nettoliquiditeiten 2022 | 17,76 mln. 16,34 mln. | Nettoliquiditeiten 2023 | 936K 862K | EV/omzet 2023 | - |
K/w-verhouding 2022 |
-3,95
x | K/w-verhouding 2023 |
-3,29
x | Werknemers | - |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 32,56% |
Recentste transcriptie over Tiziana Life Sciences PLC
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Gabriele Cerrone
CEO | Chief Executive Officer | 52 | 11-02-98 |
Keeren Shah
DFI | Director of Finance/CFO | 47 | - |
Vaseem Palejwala
CTO | Chief Tech/Sci/R&D Officer | - | 01-01-17 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
John Brancaccio
BRD | Director/Board Member | 76 | 01-07-20 |
Willy Simon
BRD | Director/Board Member | 72 | 01-11-15 |
Gabriele Cerrone
CEO | Chief Executive Officer | 52 | 11-02-98 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+31,50% | 49,46 mld. | |
+1,14% | 42,58 mld. | |
+49,00% | 42,49 mld. | |
-5,26% | 29,09 mld. | |
+12,54% | 26,61 mld. | |
-23,64% | 18,64 mld. | |
+7,47% | 13,16 mld. | |
+30,97% | 12,55 mld. | |
+23,72% | 12,1 mld. |
- Beurs
- Aandelen
- Koers TLSA
- Koers